FilingPulse

ENGN insider transaction filings

enGene Therapeutics Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-17. Screen ENGN transaction legs live →

Insider transaction summary — last 90 days

No Form 4 filings for ENGN between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.

Recent Form 4 filings — enGene Therapeutics Inc.

FiledFormInsiderReported transactionsSource
2026-06-174Joustra Wouter — DirectorGrant/award (A): 31,000 (derivative) @ $0EDGAR
2026-06-174Grossman William — Interim Chief Medical Officer, DirectorGrant/award (A): 31,000 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0EDGAR
2026-06-174Heffernan Michael Thomas — DirectorGrant/award (A): 31,000 (derivative) @ $0EDGAR
2026-06-174BRUNK GERALD A — DirectorGrant/award (A): 31,000 (derivative) @ $0EDGAR
2026-06-174Astley-Sparke Philip — DirectorGrant/award (A): 31,000 (derivative) @ $0EDGAR
2026-06-174Glickman Richard M — DirectorGrant/award (A): 31,000 (derivative) @ $0EDGAR
2026-06-174HASTINGS PAUL J — DirectorGrant/award (A): 31,000 (derivative) @ $0EDGAR
2026-06-174Zoth Lota S. — DirectorGrant/award (A): 31,000 (derivative) @ $0EDGAR
2026-02-034CHEUNG ANTHONY TZEYEW — Chief Scientific OfficerGrant/award (A): 195,000 (derivative) @ $0EDGAR
2026-02-034Nichols Alexander Julian — Chief Strategy & Ops. OfcGrant/award (A): 195,000 (derivative) @ $0EDGAR
2026-02-034Connolly Joan — Chief Technology OfficerGrant/award (A): 195,000 (derivative) @ $0EDGAR
2026-02-034Boyd Matthew Ross — Chief Regulatory OfficerGrant/award (A): 195,000 (derivative) @ $0EDGAR
2026-02-034Giguere Lee — Chief Legal Ofc. and Corp SecyGrant/award (A): 195,000 (derivative) @ $0EDGAR
2026-02-034Buck Jill — Chief Development OfficerGrant/award (A): 195,000 (derivative) @ $0EDGAR
2026-02-034Cooper Ronald Harold Wilfred — CEO & President, DirectorGrant/award (A): 801,000 (derivative) @ $0EDGAR
2026-02-034Daws D. Ryan — Chief Financial OfficerGrant/award (A): 220,000 (derivative) @ $0EDGAR
2025-10-014Sweiti Hussein — Chief Medical OfficerGrant/award (A): 600,000 (derivative) @ $0EDGAR
2025-07-144Boyd Matthew Ross — Chief Regulatory OfficerGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-07-104Buck Jill — Chief Development OfficerGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-07-104Grossman William — DirectorGrant/award (A): 45,000 (derivative) @ $0EDGAR
2025-07-104Heffernan Michael Thomas — DirectorGrant/award (A): 45,000 (derivative) @ $0EDGAR
2025-07-104Astley-Sparke Philip — DirectorGrant/award (A): 45,000 (derivative) @ $0EDGAR
2025-06-164Joustra Wouter — DirectorGrant/award (A): 22,500 (derivative) @ $0EDGAR
2025-06-164Bos Jasper — DirectorGrant/award (A): 22,500 (derivative) @ $0EDGAR
2025-06-164Pott Amy — Chief Global Comm. Ofc.Grant/award (A): 400,000 (derivative) @ $0EDGAR
2025-06-164BRUNK GERALD A — DirectorGrant/award (A): 22,500 (derivative) @ $0EDGAR
2025-06-164Glickman Richard M — DirectorGrant/award (A): 22,500 (derivative) @ $0EDGAR
2025-06-164HASTINGS PAUL J — DirectorGrant/award (A): 22,500 (derivative) @ $0EDGAR
2025-06-164Zoth Lota S. — DirectorGrant/award (A): 22,500 (derivative) @ $0EDGAR
2025-01-314Pruthi Raj Som — Chief Medical OfficerGrant/award (A): 280,000 (derivative) @ $0EDGAR
2025-01-314Nichols Alexander Julian — Chief Strategy & Ops. OfcGrant/award (A): 250,000 (derivative) @ $0EDGAR
2025-01-314CHEUNG ANTHONY TZEYEW — Chief Scientific OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2025-01-314Giguere Lee — Chief Legal Ofc. and Corp SecyGrant/award (A): 250,000 (derivative) @ $0EDGAR
2025-01-314Cooper Ronald Harold Wilfred — CEO & President, DirectorGrant/award (A): 850,000 (derivative) @ $0EDGAR
2025-01-314Daws D. Ryan — Chief Financial OfficerGrant/award (A): 280,000 (derivative) @ $0EDGAR
2024-11-014Forbion Growth Opportunities Fund I Cooperatief U.A. — 10% owner
Forbion Growth Management B.V. — 10% owner		Purchase (P): 561,797 @ $8.90EDGAR
2024-10-224CHEUNG ANTHONY TZEYEW — Chief Scientific OfficerGrant/award (A): 100,000 (derivative) @ $0EDGAR
2024-10-224Connolly Joan — Chief Technology OfficerGrant/award (A): 210,000 (derivative) @ $0EDGAR
2024-10-184Forbion Growth Opportunities Fund I Cooperatief U.A. — 10% owner
Forbion Growth Management B.V. — 10% owner		Purchase (P): 2,750 @ $7.17 · Purchase (P): 5,050 @ $7.69 · Purchase (P): 400 @ $8.30 · Purchase (P): 9,620 @ $9.09 · Purchase (P): 38,396 @ $5.94 · Purchase (P): 3,243 @ $6.38 · +7 moreEDGAR
2024-10-014Cooper Ronald Harold Wilfred — Chief Executive Officer, DirectorPurchase (P): 10,000 @ $5.70EDGAR
2024-07-254Pruthi Raj Som — Chief Medical OfficerGrant/award (A): 110,000 (derivative) @ $0EDGAR
2024-07-244Cooper Ronald Harold Wilfred — Chief Executive Officer, DirectorGrant/award (A): 1,250,000 (derivative) @ $0EDGAR
2024-06-184Joustra Wouter — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-06-184Bos Jasper — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2024-06-184BRUNK GERALD A — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2024-06-184Glickman Richard M — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2024-06-184HASTINGS PAUL J — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-06-184Zoth Lota S. — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2024-05-294Glickman Richard M — DirectorOption exercise (M): 120 @ $0.89 · Option exercise (M): 120 (derivative) @ $0EDGAR
2024-04-224FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC — 10% ownerSale (S): 4,575 @ $15.01 · Sale (S): 100 @ $15 · Sale (S): 47,854 @ $15EDGAR

Recent 8-K events — enGene Therapeutics Inc.

FiledFormItems reportedSource
2026-09-088-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-08-118-K8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-07-178-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits		EDGAR
2026-07-168-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits		EDGAR
2026-06-188-K/A?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers		EDGAR
2026-06-158-K2.02 — Results of Operations and Financial Condition
?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-06-108-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits		EDGAR
2026-05-078-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-04-098-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits		EDGAR
2026-03-098-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ENGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →